Screener
Stoke Therapeutics, Inc. STOK Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Deferred revenue - current portion | 10,066 | 11,901 |
| Total current liabilities | $40,806 | $57,875 |
| Deferred revenue - net of current portion | 6,603 | 6,961 |
| Other long-term liabilities | 991 | 1,141 |
| Total long-term liabilities | 7,594 | 8,102 |
| Total liabilities | $48,400 | $65,977 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s other non-current liabilities?
- Stoke Therapeutics, Inc. (STOK) reported other non-current liabilities of $991K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s other non-current liabilities changed year-over-year?
- Stoke Therapeutics, Inc.'s other non-current liabilities decreased by 47.1% year-over-year, from $1.87M to $991K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s other non-current liabilities?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s other non-current liabilities has grown at a -26.7% compound annual growth rate (CAGR), from $3.95M to $1.14M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Stoke Therapeutics, Inc.'s other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude